Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Galapagos NV

< Previous 1 2 Next >
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
From Galapagos NV
Via GlobeNewswire
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
From Galapagos NV
Via GlobeNewswire
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
From Galapagos NV
Via GlobeNewswire
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023
From Galapagos NV
Via GlobeNewswire
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
From Galapagos NV
Via GlobeNewswire
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
From Galapagos NV
Via GlobeNewswire
Galapagos appoints Simon Sturge to its Board of Directors
From Galapagos NV
Via GlobeNewswire
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
From Galapagos NV
Via GlobeNewswire
Galapagos announces first half-year 2023 financial results
From Galapagos NV
Via GlobeNewswire
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
From Galapagos NV
Via GlobeNewswire
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
From Galapagos NV
Via GlobeNewswire
Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress
From Galapagos NV
Via GlobeNewswire
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
From Galapagos NV
Via GlobeNewswire
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
From Galapagos NV
Via GlobeNewswire
Galapagos creates new subscription right plans
From Galapagos NV
Via GlobeNewswire
Galapagos announces first quarter 2023 financial results
From Galapagos NV
Via GlobeNewswire
Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer
From Galapagos NV
Via GlobeNewswire
Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
From Galapagos NV
Via GlobeNewswire
Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting
From Galapagos NV
Via GlobeNewswire
Galapagos and NovAliX enter into an integrated drug discovery collaboration
From Galapagos NV
Via GlobeNewswire
Galapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting
From Galapagos NV
Via GlobeNewswire
Galapagos increases share capital through subscription right exercises
From Galapagos NV
Via GlobeNewswire
Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
From Galapagos NV
Via GlobeNewswire
Galapagos announces full year 2022 results and outlook for 2023
From Galapagos NV
Via GlobeNewswire
Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL
From Galapagos NV
Via GlobeNewswire
Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease
From Galapagos NV
Via GlobeNewswire
Galapagos receives transparency notification from FMR LLC
From Galapagos NV
Via GlobeNewswire
Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference
From Galapagos NV
Via GlobeNewswire
Galapagos receives transparency notification from FMR LLC
From Galapagos NV
Via GlobeNewswire
Galapagos announces changes to Executive Committee
From Galapagos NV
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.